Ripasudil: First global approval

Drugs

Volumn 74, Issue 18, 2014, Pages 2211-2215

  Garnock Jones, Karly P ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

RHO KINASE; RIPASUDIL; ANTIHYPERTENSIVE AGENT; EYE DROPS; ISOQUINOLINE DERIVATIVE; K-115; SULFONAMIDE;

ABNORMAL SENSATION; AQUEOUS HUMOR FLOW; AQUEOUS HUMOR OUTFLOW; ARTICLE; ASTHMA; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; DIABETIC RETINOPATHY; DRUG APPROVAL; DRUG INFORMATION; DRUG METABOLISM; ELIMINATION HALF-LIFE; ENZYME INHIBITION; EYE DISCOMFORT; EYE IRRITATION; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); PATENT; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOPHOBIA; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL CLEARANCE; SCHLEMM CANAL; TRABECULAR MESHWORK; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG APPROVAL; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; ISOQUINOLINES; OPHTHALMIC SOLUTIONS; RHO-ASSOCIATED KINASES; SULFONAMIDES; TRABECULAR MESHWORK; TREATMENT OUTCOME;

EID: 84922102262     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0333-2     Document Type: Article

References (20)

1. Novack GD. RHO kinase inhibitors for the treatment of glaucoma. Drugs Future. 2013;38(2):107-13.
2. Bucolo C, Salomone S, Drago F, et al. Pharmacological management of ocular hypertension: current approaches and future prospective. Curr Opin Pharmacol. 2013;13(1):50-5.
3. Isobe T, Mizuno K, Kaneko Y, et al. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res. 2014;39(8):813-22.
4. D. Western Therapeutics Institute. DWTI announces the acquisition of marketing approval in japan for a drug for treating glaucoma and ocular hypertension, K-115 [media release]. 26 Sept 2014. http://www.dwti.co.jp.
5. D. Western Therapeutics Institute Inc. Notice of NDA application in Japan for a glaucoma treatment drug "K-115 (nonproprietary name: Ripasudil hydrochloride hydrate" by Kowa Company Limited [media release]. 10 Oct 2013. http://www.dwti.co.jp.
6. D. Western Therapeutics Institute Inc. Notice of completion of late phase III clinical study of glaucoma treatment drug "K-115" in Japan [media release]. 10 Apr 2013. http://www.dwti.co.jp.
7. Kowa Company Ltd. K-115 Clinical pharmacology study [JAPIC identifier JapicCTI-142456]. 2014. http://clinicaltrials.jp. Accessed 22 Oct 2014.
8. D. Western Therapeutics Institute. Anti-glaucoma K-115 (Glanatec® ophthalmic solution 0.4 %). 2014. http://dwti.co.jp/english/business-outline/product-pipeline/anti-glaucoma-k-115. Accessed 23 Oct 2014.
9. Mizuno K, Matsumoto J. United States Patent No. US 8,193,193 B2: agent for prevention or treatment of glaucoma. 2012. http://patft.uspto.gov/. Accessed 23 Oct 2014.
10. Wato E, Omichi K, Yoneyama S, et al. Safety evaluation of morphological changes in corneal endothelial cells induced by K-115 in cynomolgus monkeys. Fundam Toxicol Sci. 2014;1(2):39-47.
11. Tanihara HMD, Inoue TMD, Yamamoto TMD, et al. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131(10):1288-95.
12. Nakao S, Arita R, Isobe T, et al. Therapeutic potential of topical ROCK inhibitor K-115 in retinal neovascularization [abstract no. FP-SA-51-4]. In: World Ophthalmology Congress. Tokyo; 2014.
13. Yoshioka T, Nakabayashi S, Nagaoka T, et al. Effect of intravitreal Rho kinase inhibitors on retinal microcirculation in cats [abstract no. 6855-D1185]. In: Association for research in vision and ophthalmology annual meeting. Fort Lauderdale; 2012.
14. Yamamoto K, Maruyama K, Himori N, et al. The novel Rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma. Invest Ophthalmol Vis Sci. 2014. doi: 10.1167/iovs.13-13842.
15. Mizuno K, Koide T, Fujieda J, et al. Ocular hypotensive and neuroprotective effects on K-115, a novel Rho-kinase inhibitor [abstract no. 4805-B998]. Invest Ophthalmol Vis Sci. 2007;48.
16. Japanese Pharmaceuticals and Medical Devices Agency. Glanatec® (ripasudil hydrochloride hydrate ophthalmic solution 0.4 %): Japanese prescribing information. 2014. http://www.info.pmda.go.jp/. Accessed 22 Oct 2014.
17. Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156(4):731-6.
18. Yamamoto T, Abe H, Kuwayama Y, et al. Efficacy and safety of the Rho kinase inhibitor, K-115, over 24 h in patients with primary open-angle glaucoma and ocular hypertension [abstract no. 216/A512]. In: Association for research in vision and ophthalmology annual meeting. Orlando; 2011.
19. Yamamoto T, Tanihara H, Kuwayama Y, et al. Phase 3 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension [abstract no. FP-TH-12-6]. In: World Ophthalmology Congress. Tokyo; 2014.
20. Tanihara H, Yamamoto T, Kuwayama Y, et al. Phase 3 randomized clinical studies of a Rho kinase inhibitor, K-115, in combination with timolol or latanoprost in primary open-angle glaucoma and ocular hypertension [abstract no. FP-TH-12-7]. In: World Ophthalmology Congress. Tokyo; 2014.